KALA BIO, Inc. Common Stock
Symbol: KALA (NASDAQ)
0.84
▼ (-10.22%) -0.095
Company Description:
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Key Stats
- Today's Open: $0.912
- Today's High: $0.928
- Today's Low: $0.812
- Today's Volume: 651.61K
- Yesterday Close: $0.9301
- Yesterday High: $0.982
- Yesterday Low: $0.853
- Yesterday Volume: 871.42K
- Last Min Volume: 1.50K
- Last Min High: $0.835
- Last Min Low: $0.835
- Last Min VWAP: $0.835
Company Profile
- Name: KALA BIO, Inc. Common Stock
- Website: https://www.kalarx.com
- Listed Date: 2017-07-20
- Location: ARLINGTON, MA
- Market Status: Active
- CIK Number: 0001479419
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $6.53M
- Round Lot: 100
- Outstanding Shares: 7.02M
- Asset Type: CS
RECENT FILINGS FOR KALA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-22 | 144 | View |
| 2025-10-22 | 144 | View |
| 2025-10-22 | 144 | View |
| 2025-10-22 | 144 | View |
| 2025-10-20 | 8-K | View |
| 2025-10-15 | SCHEDULE 13D/A | View |
| 2025-10-03 | SCHEDULE 13G | View |
| 2025-10-02 | SCHEDULE 13D/A | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 8-K/A | View |
| 2025-10-01 | SCHEDULE 13D/A | View |
| 2025-10-01 | 8-K | View |
| 2025-09-29 | 8-K | View |
| 2025-09-18 | 8-K | View |
| 2025-09-11 | SCHEDULE 13G | View |
| 2025-09-11 | SCHEDULE 13G | View |
| 2025-09-02 | 4 | View |
| 2025-09-02 | 8-K | View |
| 2025-08-08 | 10-Q | View |
| 2025-08-08 | 8-K | View |
Latest News on KALA